Tag:

Cervarix

Latest Headlines

Latest Headlines

Merck, Sanofi hope for sales expansion with two-dose Gardasil switch

Now that the European Commission has officially approved a two-dose Gardasil regimen for early teens, Merck and Sanofi will see the number of shots per patient fall. But that doesn't mean they'll necessarily take a sales hit, with the move potentially expanding overall access and providing a bump both drugmakers could use.

Government call for more HPV vaccination could boost GSK and Merck

The President's Cancer Panel is urging federal and state health authorities to do a better job protecting children from preventable cancers by improving access to the HPV vaccine, which could mean a big bump in sales.

Study: Merck's and GSK's HPV vaccines don't encourage risky sex

When the Centers for Disease Control and Prevention looked into the reasons behind low uptake of GlaxoSmithKline's and Merck's human papillomavirus vaccines last year, the effect of parental attitudes to sex grabbed the headlines. Yet while parents may fear the vaccine will lead to risky sex, all the evidence suggests otherwise.

Merck, Glaxo HPV vaccines held back by more than sex and money

A new study in JAMA Pediatrics finds that sex and money each play a role in U.S. parents' reluctance to vaccinate their children against the human papillomavirus. But a lack of easy-to-understand information about the shots--and often, the lack of a doctor's clear recommendation for them--are also helping to depress vaccination rates.

Study finds one HPV vaccine dose gives strong, durable immune response

While half of U.S. teenage girls receive one dose of human papillomavirus vaccine, far fewer come back to complete the regimen. What is less clear is whether one dose offers any protection, but a new study offers some hope.

Study suggests GSK's Cervarix can prevent throat cancer

The public health push to vaccinate both boys and girls against human papillomavirus has been hindered by a lack of studies showing that the jabs prevent forms of cancer other than cervical. Now data on throat cancer are emerging a week after an anal disease study.

HPV vax awareness uneven despite Merck ad blitz

In 2007, Merck spent $100 million promoting its human papillomavirus vaccine, Gardasil. The advertising blitz helped sales top $1 billion, but earnings fell away quickly over the next few years. Many people are critical of the vaccine, but lots more simply do not know it exists.

GlaxoSmithKline, Merck offer GAVI 95% discount on HPV vaccines

GlaxoSmithKline and Merck are slashing the prices of their HPV vaccinations in a deal with the GAVI Alliance, which delivers immunizations to the developing world.

GSK, Merck agree on HPV vax discount with GAVI

Social issues have held back uptake of GlaxoSmithKline and Merck human papillomavirus (HPV) vaccines in the U.S., but globally the problem is more fundamental--the shots cost too much. It is these low-income countries--where 85% of cervical cancer cases occur--that need the vaccines most though.

Merck's Gardasil looks effective in two-shot regimen

New research suggests that two doses of human papillomavirus vaccine could be as effective as the current three-dose regimen, which would increase uptake.